Based on trading patterns, the ACB stock forecast anticipates sideways movement unless strong earnings catalysts arrive. Support zones are holding at CAD 0.81, while momentum traders eye resistance near CAD 1.09. The FDA has been regulating vaping products since 2016, claiming that flavored vapes represent a health concern and may encourage young people to use tobacco. More than 2.1 million youths in the US reported using e-cigarettes in 2023, with 10% of high school students vaping. The FDA has rejected thousands of flavored products and has only approved tobacco and menthol flavors. One specific issue, marketing plan consideration, was returned to lower courts after the Supreme Court reversed the 5th Circuit’s prior criticism of the FDA’s changing criteria. Companies that promote unapproved products risk “civil and criminal penalties,” the FDA warned. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>. Analyst consensus in current ACB stock forecast reports points to “Hold” recommendations, awaiting clear catalysts. Price action hovering around CAD 0.86 reflects uncertainty tied to cannabis taxation policies.